Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 9, 2026

‘Buckle up!’: CNBC anchor shocked as US trade deficit plunges to lowest since 2009. How to take advantage in 2026

View original at finance.yahoo.com
‘Buckle up!’: CNBC anchor shocked as US trade deficit plunges to lowest since 2009. How to take advantage in 2026 Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The economy is expected to strengthen in 2026 due to fading policy uncertainty, tax cuts, and loosening monetary policy

    80% confidence
  • People don't typically have an adequate amount of gold in their portfolio

    80% confidence
  • Gold can easily rise to $10,000 an ounce in current environment

    80% confidence
  • The stock market and 401(k)s are the only things really going up big

    80% confidence
  • The October trade deficit of $29.4 billion is approximately half of economists' expectations of $58 billion

    80% confidence
  • Imports were down and exports were up, explaining the trade deficit reduction

    80% confidence
  • For most people, the best thing to do is own the S&P 500 index fund

    80% confidence
  • Would purchase 1% of all apartment houses in the country for $25 billion if offered

    80% confidence
  • The March trade deficit was $136 billion compared to current $29.4 billion

    80% confidence
  • Forecasts for a U.S. recession are coming up dry as productivity continues to backstop growth

    80% confidence
  • The U.S. appears to be winning the trade war with tariffs curbing imports while trading partners continue buying American goods

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com